Immix Biopharma, Inc. (IMMX)
NASDAQ: IMMX · Real-Time Price · USD
2.970
+0.050 (1.71%)
At close: Jul 18, 2025, 4:00 PM
2.930
-0.040 (-1.35%)
After-hours: Jul 18, 2025, 7:53 PM EDT
Company Description
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia.
The company’ lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab.
Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Immix Biopharma, Inc.
| Country | United States |
| Founded | 2014 |
| IPO Date | Dec 16, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Ilya Rachman |
Contact Details
Address: 11400 West Olympic Boulevard, Suite 200 Los Angeles, California 90064 United States | |
| Phone | 310 651 8041 |
| Website | immixbio.com |
Stock Details
| Ticker Symbol | IMMX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001873835 |
| CUSIP Number | 45258H106 |
| ISIN Number | US45258H1068 |
| Employer ID | 45-4869378 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D. | Co-Founder, Chief Executive Officer and Chairman |
| Gabriel Morris B.A. | Chief Financial Officer and Director |
| Dr. Graham Ross FFPM, M.D. | Chief Medical Officer and Head of Clinical Development |
| Sean Senn J.D., M.B.A., M.Sc., MBA, MSc | Co-Founder |
| Dr. Vladimir P. Torchilin D.Sc., MSE, Ph.D. | Scientific Co-Founder |
| Dr. David Marks MBBS, Ph.D. | Chief Medical Officer of Cell Therapy |
| Gerhard Bauer | Head of Cell Therapy Manufacturing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 23, 2025 | 8-K | Current Report |
| Jun 3, 2025 | 424B5 | Filing |
| Jun 3, 2025 | 8-K | Current Report |
| May 19, 2025 | ARS | Filing |
| May 19, 2025 | 10-Q/A | [Amend] Quarterly report |
| May 19, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 19, 2025 | 10-K/A | [Amend] Annual report |
| May 8, 2025 | 10-Q | Quarterly Report |
| May 5, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 30, 2025 | DEF 14A | Other definitive proxy statements |